---
title: "Nipah virus: emerging health risks and corporate responsibilities."
description: "Nipah virus: emerging health risks and corporate responsibilities"
---

[Ambimed per le aziende ](https://www.ambimed-group.com/en/ambimed-per-le-aziende)

# [Nipah virus: emerging health risks and corporate responsibilities.](https://www.ambimed-group.com/en/ambimed-per-le-aziende/virus-nipah-rischi-sanitari-emergenti-e-responsabilità-aziendali)

 Written by [Ambimed team](https://www.ambimed-group.com/en/ambimed-per-le-aziende/author/ambimed-team) | Feb 4, 2026 8:00:01 AM

The recent report of a **Nipah virus** outbreak **in India**, with confirmed cases also among healthcare workers, draws the attention of companies that employ **staff traveling internationally** or operating in health-risk areas. In a context of increasing global mobility, preventive management of biological risks becomes a key element of **travel risk management** and worker health protection policies.

In recent days, a new outbreak of **Nipah virus** has been reported in the state of *West Bengal*, India, after confirmed cases were identified among healthcare personnel at a private hospital in **Barasat**. This event has raised international alert, especially in some South and Southeast Asian countries such as **Thailand, Nepal, and Taiwan**, which have intensified health checks and border surveillance for travelers from the affected areas.

*Nipah virus* is a **zoonotic pathogen with high lethality**, transmitted mainly by fruit bats or through consumption of contaminated food. Documented outbreaks in the past have had mortality rates ranging from **40% to 75%**, while there are no currently **approved vaccines or specific therapies**.

👉 The confirmed cases in India involve two health care workers aged about 25 years who were hospitalized and isolated in specialized facilities. Indian health authorities have activated **contact tracing activities and preventive quarantines**, involving about 200 potentially exposed people, all of whom are currently asymptomatic and have negative tests.

Despite the international alert, the **World Health Organization (WHO)** has assessed the risk of spread outside India as **low**, as no significant increase in human-to-human transmission has been observed and no case exports through travel have been detected. As a result, **no restrictions on** global **travel or trade were recommended**.

Meanwhile, several Asian countries have reintroduced **health screening measures at airports** inspired by anti-COVID protocols. These include:

- **body temperature checks of** passengers,
- **health declaration forms** upon departure or arrival,
- preliminary clinical assessments for signs of fever or compatible symptoms,
- **possible quarantine or secondary evaluation** for symptomatic passengers.

As evidenced by these measures, **Travel Medicine plays a crucial role** in protecting public health, especially in the context of global mobility still recovering from the COVID-19 pandemic. The experience accumulated in recent years shows how important this is:  
✅ to continuously update **travel recommendations**;  
✅ share timely information on emerging outbreaks;  
✅ support travelers with evidence-based prevention guidelines;  
✅ collaborate with international health authorities for coordinated responses.

Against a backdrop of **emerging outbreaks, unpredictable health risks, and rapidly changing epidemiological environments**, companies with **global interests and internationally mobile staff** cannot rely on improvised solutions or fragmented information.

Relying on **partners specializing in Travel Medicine** means integrating travelers' health within a structured **Travel Risk Management** strategy, based on:

- continuous monitoring of international health risks,
- pre-trip assessments customized by destination and task,
- prevention and response protocols in case of health emergencies,
- qualified medical support before, during, and after travel.

Investing in a **Travel Health Policy** is not just a health protection measure, but a **strategic choice** that contributes to **business continuity**, regulatory compliance and the company's accountability to its employees.

In an increasingly interconnected world, **safe travel requires specialized expertise**; therefore, companies operating internationally must have reliable partners who can anticipate risks and turn preventive health care into a real competitive advantage.

<https://www.ambimed-group.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKYG2xE6VFR%2BgaQQynfOkacCnLyKXpSowrgm9QZGh8dFOfgWXo3Ius%2Bv4SR1fyKTSvz2HLl6YC2%2FSGc1uQAL6zgEj%2FpVCGHlStSf6P2x7JHJ97ovZSMItQmQyZ8OX2n8uyudXLwTQgZV%2FE%2FIxSq%2BcJnq4aVKvYwy%2B%2BzT66uBMYEj7qUB%2BJHS4zlM3gmHPggXyed2MzaiQY%3D&webInteractiveContentId=117936736448&portalId=144804357>

[View full post](https://www.ambimed-group.com/en/ambimed-per-le-aziende/virus-nipah-rischi-sanitari-emergenti-e-responsabilità-aziendali)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Ambimed team"
  },
  "dateModified" : "2026-02-04T08:00:01.613Z",
  "datePublished" : "2026-02-04T08:00:01Z",
  "headline" : "Nipah virus: emerging health risks and corporate responsibility.",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1536,
    "url" : "https://144804357.fs1.hubspotusercontent-eu1.net/hubfs/144804357/virus%20nipah%20infografica_rev.png",
    "width" : 2752
  },
  "mainEntityOfPage" : "https://www.ambimed-group.com/en/ambimed-per-le-aziende/virus-nipah-rischi-sanitari-emergenti-e-responsabilità-aziendali",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Ambimed per le aziende"
  }
}
```